Disrupting the Palbociclib‐Induced AKR1B10 ‐ PI3K / AKT / mTOR Axis by Everolimus Synergistically Suppresses Head and Neck Squamous Cell Carcinoma Progression
Head and neck squamous cell carcinoma (HNSCC) is frequently accompanied by amplification of the 11q13 region and inactivating mutations in CDKN2A, leading to abnormal CDK4/6 activation. Treatment with the CDK4/6 inhibitor palbociclib has demonstrated efficacy in HNSCC. However, monotherapy with palbociclib can induce compensatory activation of the PI3K/AKT/mTOR signaling pathway, leading to the development of acquired resistance. This study aimed to investigate the antitumor efficacy of the CDK4/6 inhibitor palbociclib combined with the mTOR inhibitor everolimus in HNSCC and to elucidate the potential molecular mechanism of their synergistic effect. We investigated the synergistic therapeutic effects of palbociclib and everolimus in HNSCC by using CCK-8, EdU, scratch assay, transwell, flow cytometry, nude mouse xenograft and orthotopic tumor models. The potential molecular mechanisms of their synergistic effect were explored through RNA sequencing (RNA-seq), real-time quantitative PCR (RT-qPCR), and western blotting. The results demonstrated that palbociclib and everolimus exhibit significant synergistic antitumor activity in HNSCC. In vitro experiments confirmed that combined administration significantly inhibits proliferation of HNSCC cell lines, blocks cell cycle progression, and induces apoptosis. In vivo xenograft models in nude mice showed that the combination therapy effectively suppresses tumor growth without inducing significant systemic toxicity. Mechanistic studies revealed that palbociclib monotherapy induces upregulation of AKR1B10 expression. In addition, AKR1B10 interacts with PI3K, leading to further activation of the PI3K/AKT/mTOR pathway. Everolimus could reverse this process by blocking the compensatory activation of the AKR1B10/PI3K/AKT/mTOR pathway, thus exerting a synergistic effect. The combination of palbociclib and everolimus exhibited significant synergistic antitumor activity in HNSCC. This study provides a novel combination therapy strategy for HNSCC with important clinical translational significance.
Authors
- Zhu Tao (ORCID: https://orcid.org/0000-0001-8778-0668)
- Minghua Ge (ORCID: https://orcid.org/0000-0001-6726-6418)
- Jiakuo Gu (ORCID: https://orcid.org/0009-0005-7279-3438)
- 郑菊艳 (ORCID: https://orcid.org/0000-0002-6951-8233)
- Siyu Han (ORCID: https://orcid.org/0009-0004-5001-6972)
- Mengyu Chen
- Tian Dai
- Wenlu Wang
- Yafang Chen
Institutions
- Zhejiang Cancer Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Hangzhou Medical College (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- The FASEB Journal
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1096/fj.202601169r
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Medical and Health Research Project of Zhejiang Province